Avanos Medical (NYSE:AVNS) Stock Price Up 0.5% – Here’s What Happened

Avanos Medical, Inc. (NYSE:AVNS) was up 0.5% during trading on Tuesday . The stock traded as high as $12.49 and last traded at $12.40. Approximately 597,632 shares changed hands during trading, an increase of 35% from the average daily volume of 443,140 shares. The stock had previously closed at $12.34.

Analysts Set New Price Targets

A number of research firms recently commented on AVNS. Zacks Research cut shares of Avanos Medical from a “hold” rating to a “strong sell” rating in a research note on Monday, December 1st. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. Two analysts have rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Avanos Medical Stock Up 0.5%

The company has a market cap of $575.61 million, a PE ratio of -1.22 and a beta of 1.08. The company’s 50 day moving average is $11.62 and its 200 day moving average is $11.60. The company has a current ratio of 2.38, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.10. The company had revenue of $177.80 million during the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.33 EPS. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, analysts predict that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Kerr Holbrook sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total value of $165,000.00. Following the transaction, the senior vice president owned 83,860 shares of the company’s stock, valued at $922,460. This represents a 15.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.64% of the company’s stock.

Institutional Investors Weigh In On Avanos Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Avanos Medical during the second quarter valued at approximately $192,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Avanos Medical during the second quarter worth $262,000. Squarepoint Ops LLC bought a new stake in Avanos Medical during the 2nd quarter valued at $1,145,000. Strs Ohio purchased a new position in shares of Avanos Medical in the 1st quarter valued at $460,000. Finally, AlphaQuest LLC raised its position in shares of Avanos Medical by 58.5% in the 2nd quarter. AlphaQuest LLC now owns 37,091 shares of the company’s stock worth $454,000 after acquiring an additional 13,692 shares in the last quarter. 95.17% of the stock is owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.